Applications of Nanoparticles in Treatment of Respiratory Disorders
Abstract
Respiratory disorders are very prevalent and high-incidence group of diseases having severe impacts on human
health in the world. Some of the respiratory disorders are difficult to diagnose and treat, such as chronic
obstructive pulmonary disease, asthma, lungs cancer, and pulmonary tuberculosis. Lungs cancer is the second
most common cancer globally. Nano-delivery technologies have a great potential to improve the drug targeting
in a specific area of infections in respiratory disease treatment. Not only nanoparticles concentrate the drug at
specific-disease sites but also reduce the drug degradation and drug loss simultaneously. Sedimentation,
nebulizers, carbon nanodots, and stimulus-responsive nanoparticles are currently being explored to use as a
source for delivering nanodrugs to treat lungs cancer. Various nanoparticles such as steroids, salbutamol,
liposome-mediated, and polystyrene are used in the treatment of asthma and preterm birth diseases. This
study focused on different kinds of nanoparticles like gold, solid lipid nanoparticles (NPs), steroidal and
liposome-mediated nanoparticles which are used to treat different pulmonary or respiratory disorders and also
examine the current therapeutic techniques for the diagnosis of lung diseases and therapy using nanoscalebased
inhalers.
References
Majdalawieh A, Kanan MC, El-Kadri O, Kanan SM. Recent advances in gold and silver nanoparticles: synthesis and applications. Journal of nanoscience and nanotechnology. 2014; 14: 4757-80.
Dames P, Gleich B, Flemmer A, Hajek K, Seidl N, Wiekhorst F, et al. Targeted delivery of magnetic aerosol droplets to the lung. Nature nanotechnology. 2007; 2: 495-9.
Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. journal of Advanced Drug Delivery Reviews 2012; 64: 24-36.
Schneider CS, Xu Q, Boylan NJ, Chisholm J, Tang BC, Schuster BS, et al. Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation. Science advances. 2017; 3: e1601556.
Prow TW, Grice JE, Lin LL, Faye R, Butler M, Becker W, et al. Nanoparticles and microparticles for skin drug delivery. Advanced drug delivery reviews. 2011; 63: 470-91.
Baroli B. Penetration of nanoparticles and nanomaterials in the skin: fiction or reality?. Journal of pharmaceutical sciences. 2010; 99: 21-50.
Kang H, Han M, Xue J, Baek Y, Chang J, Hu S, et al. Renal clearable nanochelators for iron overload therapy. Nature communications. 2019; 10: 1-1.
Bicker J, Alves G, Fortuna A, Falcão A. Blood–brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review. European Journal of Pharmaceutics and Biopharmaceutics. 2014; 87: 409-32.
Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment and their
performance. Signal transduction and targeted therapy. 2018; 3: 1-9.
Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacological reports. 2012; 64: 1020-37.
Alyautdin R, Gothier D, Petrov V, Kharkevich D, Kreuter J. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly (butylcyanoacrylate) nanoparticles. European journal of
pharmaceutics and biopharmaceutics. 1995; 41: 44-8.
Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. Aaps Pharmscitech. 2011; 12: 62-76.
Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus
barriers. Advanced drug delivery reviews. 2012; 64: 557-70.
Makhlof A, Tozuka Y, Takeuchi H. Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery. European journal of pharmaceutical sciences. 2011; 42: 445-51.
Paranjpe M, Müller-Goymann CC. Nanoparticle-mediated pulmonary drug delivery: a review. International journal of molecular sciences. 2014; 15: 5852-73.
Schürch S, Gehr P, Im Hof V, Geiser M, Green F. Surfactant displaces particles toward the epithelium in airways and alveoli. Respiration physiology. 1990; 80: 17-32.
Geiser M, Rothen-Rutishauser B, Kapp N, Schürch S, Kreyling W, Schulz H, Semmler M, et al. Ultrafine particles
cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. Environmental health
perspectives. 2005; 113: 1555-60.
Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. European journal of pharmaceutics and biopharmaceutics. 2008; 69: 1-9.
Mohanraj VJ, Chen Y. Nanoparticles – A Review. Tropical Journal of Pharmaceutical Research. 2006; 5: 561-73.
Singh R, Lillard Jr JW. Nanoparticle-based targeted drug delivery. Experimental and molecular pathology. 2009; 86: 215-23.
van Rijt SH, Bein T, Meiners S. Medical nanoparticles for next generation drug delivery to the lungs.
Majdalawieh A, Kanan MC, El-Kadri O, Kanan SM. Recent advances in gold and silver nanoparticles: synthesis and applications. Journal of nanoscience and nanotechnology. 2014; 14: 4757-80.
Schütz CA, Juillerat-Jeanneret L, Mueller H, Lynch I, Riediker M. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine. 2013; 8: 449-67.
Ealia SA, Saravanakumar MP. A review on the classification, characterisation, synthesis of nanoparticles and their application. InIOP Conference Series: Materials Science and Engineering 2017; 263: 032019.
Hussain S, Vanoirbeek JA, Haenen S, Haufroid V, Boland S, Marano F, et al. Prior lung inflammation impacts on body distribution of gold nanoparticles. BioMed research international. 2013.
Elbakary RH, Okasha EF, Ragab AM, Ragab MH. Histological effects of gold nanoparticles on the lung tissue of adult male albino rats. Journal of microscopy and ultrastructure. 2018; 6: 116.
Geiser M, Quaile O, Wenk A, Wigge C, Eigeldinger-Berthou S, Hirn S, et al. Cellular uptake and localization of inhaled gold nanoparticles in lungs of mice with chronic obstructive pulmonary disease. Particle and fibre toxicology. 2013; 10: 1-0.
Beck-Broichsitter M, Ruppert C, Schmehl T, Guenther A, Betz T, Bakowsky U, et al. Biophysical investigation of
pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro. Nanomedicine:
Nanotechnology, Biology and Medicine. 2011; 7: 341-50.
Weber S, Zimmer A, Pardeike J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics. 2014; 86: 7-22.
Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomedicine. 2011; 6: 715-28.
Schuster BS, Suk JS, Woodworth GF, Hanes J. Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials. 2013; 34: 3439-46.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021; 71: 209-49.
Azarmi S, Roa WH, Löbenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Advanced drug delivery reviews. 2008; 60: 863-75.
Strunz M, Simon LM, Ansari M, Kathiriya JJ, Angelidis I, Mayr CH, et al. Alveolar regeneration through a Krt8+ transitional stem cell state that persists in human lung fibrosis. Nature communications. 2020; 11: 1-20.
Krahl VE. Microscopic anatomy of the lungs. 1959; 80: 24- 44.
Tena AF, Clarà PC. Deposition of inhaled particles in the lungs. Archivos de Bronconeumología (English Edition). 2012; 48: 240-6.
Mangal S, Gao W, Li T, Zhou QT. Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung
ca n c e rs : c h a l l e n ge s a n d o p p o r t u n i t i e s . A c ta pharmacologica sinica. 2017; 38: 782-97.
Gobbo OL, Sjaastad K, Radomski MW, Volkov Y, Prina-Mello A. Magnetic nanoparticles in cancer theranostics.
Theranostics. 2015; 5: 1249.
H i t z m a n C J, Wa tt e n b e rg LW, W i e d m a n n T S. Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles. Journal of pharmaceutical sciences. 2006; 95: 1196-211.
Hirsch FR, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene. 2009; 28: S32-7.
Lee WH, Loo CY, Young PM, Traini D, Mason RS, Rohanizadeh R. Recent advances in curcumin nanoformulation for cancer therapy. Expert opinion on drug delivery. 2014 ; 11: 1183-201.
Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. The Lancet
Journal. 2011; 377: 1032-45.
Respaud R, Vecellio L, Diot P, Heuzé-Vourc'h N. Nebulization as a delivery method for mAbs in respiratory diseases. Expert opinion on drug delivery. 2015; 12: 1027-39.
Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery–a review of the state of the art. European journal of pharmaceutics and biopharmaceutics. 2000; 50: 161-77.
Bahadori M, Mohammadi F. Nanomedicine for respiratory diseases. Tanaffos. 2012; 11: 18-22.
Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS nano. 2009 ; 3: 16-20.
Lee WH, Loo CY, Traini D, Young PM. Inhalation of nanoparticle-based drug for lung cancer treatment:
advantages and challenges. asian journal of pharmaceutical sciences. 2015; 10: 481-9.
Yang W, Peters JI, Williams III RO. Inhaled nanoparticles—a current review. International journal of pharmaceutics. 2008; 356: 239-47.
Rao RD, Markovic SN, Anderson PM. Aerosol therapy for malignancy involving the lungs. Current cancer drug
targets. 2003; 3: 239-50.
Ally J, Martin B, Khamesee MB, Roa W, Amirfazli A. Magnetic targeting of aerosol particles for cancer therapy. Journal of magnetism and magnetic materials. 2005 ; 293: 442-9.
Zhou QT, Tang P, Leung SS, Chan JG, Chan HK. Emerging inhalation aerosol devices and strategies: where are we headed?. Advanced drug delivery reviews. 2014; 75: 3-17.
Conti DS, Brewer D, Grashik J, Avasarala S, da Rocha SR. Poly (amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium. Molecular pharmaceutics. 2014; 11: 1808-22.
Wu YF, Wu HC, Kuan CH, Lin CJ, Wang LW, Chang CW, et al. Multi-functionalized carbon dots as theranostic nanoagent for gene delivery in lung cancer therapy. Scientific reports. 2016; 6: 1-2.
Menon JU, Kuriakose A, Iyer R, Hernandez E, Gandee L, Zhang S, Tet al. Dual-drug containing core-shell
nanoparticles for lung cancer therapy. Scientific reports. 2017 ; 7: 1-3.
National Heart, Lung, Blood Institute. National Asthma Education Program. Expert Panel on the Management of Asthma. Guidelines for the Diagnosis and Management of Asthma. National Asthma Education Program, Office of Prevention, Education, and Control, National Heart, Lung, and Blood Institute, National Institutes of Health; 1991.
Cooper V, Metcalf L, Versnel J, Upton J, Walker S, Horne R. Patient-reported side effects, concerns and adherence to corticosteroid treatment for asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, cross-sectional study. NPJ primary care respiratory medicine. 2015; 25: 1-6.
Barreto E, Serra MF, Dos Santos RV, Dos Santos CE, Hickmann J, Cotias AC, et al. Local administration of gold
nanoparticles prevents pivotal pathological changes in murine models of atopic asthma. Journal of biomedical
nanotechnology. 2015; 11: 1038-50.
Liu FK, Chang YC. Using thiol-capped gold nanoparticles in the background solution of MEKC to concentrate and separate neutral steroids. Chromatographia. 2010 ; 72: 1129-35.
Ahmad FJ, Mittal G, Jain GK, Malhotra G, Khar RK, Bhatnagar A. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions. European Journal of Pharmaceutics and Biopharmaceutics. 2009; 71: 282-91.
Chen X, Huang W, Wong BC, Yin L, Wong YF, Xu M, et al. Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. International journal of nanomedicine. 2012; 7: 1139.
Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellularmechanisms. European Respiratory Journal. 2003; 22: 672-88.
Moller W, Felten K, Sommerer K, Scheuch G, Meyer G, Meyer P, et al. Deposition, retention, and translocation of ultrafine particles from the central airways and lung periphery. American journal of respiratory and critical care medicine. 2008 ; 177: 426-32.
Brandenberger C, Rothen-Rutishauser B, Mühlfeld C, Schmid O, Ferron GA, Maier KL, et al. Effects and uptake of gold nanoparticles deposited at the air–liquid interface of a human epithelial airway model. Toxicology and applied pharmacology. 2010 ; 242: 56-65.
Geiser M, Quaile O, Wenk A, Wigge C, Eigeldinger-Berthou S, Hirn S, et al. Cellular uptake and localization of inhaled gold nanoparticles in lungs of mice with chronic obstructive pulmonary disease. Particle and fibre toxicology. 2013; 10: 1-0.
Kunda NK, Alfagih IM, Miyaji EN, Figueiredo DB, Gonçalves VM, Ferreira DM, et al. Pulmonary dry powder vaccine of pneumococcal antigen loaded nanoparticles. International journal of pharmaceutics. 2015; 495: 903-12.
Kunda NK, Alfagih IM, Dennison SR, Tawfeek HM, Somavarapu S, Hutcheon GA, et al. Bovine serum albumin
adsorbed PGA-co-PDL nanocarriers for vaccine delivery via dry powder inhalation. Pharmaceutical research. 2015; 32: 1341-53.
Ai JW, Zhou X, Xu T, Yang M, Chen Y, He GQ, et al. CRISPR based rapid and ultra-sensitive diagnostic test for
Mycobacterium tuberculosis. Emerging microbes & infections. 2019; 8: 1361-9.
Tuberculosis Drug Screening Program*. Search for new drugs for treatment of tuberculosis. Antimicrobial agents and chemotherapy. 2001; 45: 1943-6.
John AE, Lukacs NW, Berlin AA, Palecanda A, Bargatze RF, Stoolman LM, et al. Discovery of a potent nanoparticle P-selectin antagonist with anti-inflammatory effects in allergic airway disease. The FASEB journal. 2003; 17: 2296- 8.
Inocencio IM, Bischof RJ, Xiang SD, Zahra VA, Nguyen V, Lim T, et al. Exacerbation of ventilation-induced lung injury and inflammation in preterm lambs by high-dose nanoparticles. Scientific reports. 2017; 7: 1-0.
Hardy CL, LeMasurier JS, Mohamud R, Yao J, Xiang SD, Rolland JM, et al. Differential uptake of nanoparticles and microparticles by pulmonary APC subsets induces discrete immunological imprints. The journal of immunology. 2013; 191: 5278-90.
